Clinical Trial Update: A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection [Phase 3]

View source ↗

Summary

This clinical trial update reports on a Phase 3 study evaluating a protease inhibitor and interleukin-2 (IL-2) for the treatment of early HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Protease inhibitor (protease inhibitor)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 3 | Status: COMPLETED